Microbix And Hunan Biopharmaceutical Group To Set Up Influenza Vaccine Production Base
This article was originally published in PharmAsia News
Executive Summary
Canada-based Microbix and Hunan Biopharmaceutical Group will jointly set up an influenza vaccine base in the Changsha National Biomedical Industrial Base. This represents the largest collaboration between China and Canada since the establishment of diplomatic relations. Both parties have reached an agreement to begin phase I construction in the first half of next year. With an investment of RMB 1.4 billion ($205 million), the project will comply with U.S. and EU standards. After completion, the facility will be the world's third largest influenza vaccine production base. (Click here for more - Chinese language)